Dr. John R. Weber, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- University of Michigan Medical School (1986)
- Years since graduation
- 40
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 572
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1986Medical school: University of Michigan Medical School
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
MI license 4301069183
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Beaumont Hospital Royal Oak Royal Oak, MI
- Beaumont Hospital, Troy Troy, MI
- Beaumont Hospital - Grosse Pointe Grosse Pointe, MI
- Beaumont Hospital - Farmington Hills Farmington Hills, MI
Medical groups
- Troy Gastroenterology PC (49 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 572
- Services billed
- 4,641
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Biopsy of large bowel using a flexible endoscope | 219 | 217 |
| Established patient office or other outpatient visit, 20-29 minutes | 218 | 149 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 171 | 161 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 90 | 90 |
| Established patient office or other outpatient visit, 30-39 minutes | 69 | 57 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 44 | 44 |
| Telephone medical discussion with physician, 11-20 minutes | 38 | 33 |
| New patient office or other outpatient visit, 30-44 minutes | 37 | 37 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 36 | 35 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 34 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Omeprazole Other prescribers in Troy, MI | 482 |
| Famotidine Other prescribers in Troy, MI | 241 |
| Pantoprazole Sodium Other prescribers in Troy, MI | 118 |
| Rabeprazole Sodium Other prescribers in Troy, MI | 66 |
| Stelara (ustekinumab) | 58 |
| Dicyclomine Hcl Other prescribers in Troy, MI | 53 |
| Sucralfate Other prescribers in Troy, MI | 48 |
| Lubiprostone Other prescribers in Troy, MI | 43 |
| Metoclopramide Hcl Other prescribers in Troy, MI | 34 |
| Mesalamine Other prescribers in Troy, MI | 31 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 57 payments worth $1,236 in total to this clinician.
| Food and Beverage | $1,068 |
|---|---|
| Education | $167 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Jul 16, 2025 | Education TREMFYA · Immunology · in-kind | $99.00 |
| AstraZeneca Pharmaceuticals LP Jul 29, 2025 | Education IMFINZI · Oncology · in-kind Company’s descriptionJournal Article | $68.49 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $6,302 in research payments for these studies, mostly to the institutions running them.
- OLE
Genentech, Inc. - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
AbbVie Inc. · Active, not recruiting · NCT03398135 - M16-066 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.